Climb Bio (NASDAQ:CLYM – Get Free Report) released its quarterly earnings results on Tuesday. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.02, Zacks reports.
Climb Bio Stock Down 2.3 %
Climb Bio stock traded down $0.03 during midday trading on Wednesday, reaching $1.27. The company’s stock had a trading volume of 87,846 shares, compared to its average volume of 374,537. The company’s 50 day simple moving average is $1.59. Climb Bio has a fifty-two week low of $1.20 and a fifty-two week high of $11.55. The company has a market capitalization of $85.37 million, a price-to-earnings ratio of -0.60 and a beta of -0.19.
Analysts Set New Price Targets
A number of brokerages recently commented on CLYM. Leerink Partners began coverage on Climb Bio in a report on Monday, December 2nd. They set an “outperform” rating and a $10.00 target price for the company. Leerink Partnrs upgraded shares of Climb Bio to a “strong-buy” rating in a report on Monday, December 2nd.
About Climb Bio
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Further Reading
- Five stocks we like better than Climb Bio
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- Energy Transfer: Powering Data With Dividends and Diversification
- What Investors Need to Know About Upcoming IPOs
- Qualcomm Stock Is Coiling for a Breakout
- How to Short Nasdaq: An Easy-to-Follow Guide
- Is Alphabet Too Cheap to Ignore After Its Recent Correction?
Receive News & Ratings for Climb Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Climb Bio and related companies with MarketBeat.com's FREE daily email newsletter.
